Medical Policy Update February 3, 2022
| Medical Guidelines | Reason for Update |
| Belimumab (Benlysta®) | Added clarification that SLE activity may be scored by a comparable standardized rating scale that reliably measures SLE disease activity. |
| Immunoglobulin Therapy | Expanded indication for Cutaquig to patients 2 years of age and older per FDA approval update. |
Blue Connect